AYTU Stock Slips Before Exxua Update Investors Are Watching
Aytu BioPharma shares slipped about 3% on Thursday, trading at $2.08, as investors waited for management’s next update on the launch of Exxua, its antidepressant, at a virtual investor conference next week. The broader biotech tape was quieter, with the SPDR S&P Biotech ETF and iShares Nasdaq Biotechnology ETF both fractionally lower. The stock move matters now because Aytu is in a narrow window: Exxua is new enough that every prescription trend counts, but the legacy ADHD and pediatric drug businesses are already shrinking. The company said it will present at the Lytham Partners Spring 2026 Investor Conference on May 28 at 9:15 a.m. Eastern time and hold one-on-one investor meetings.